Sean McGinty

Sean McGinty

Auto-generated profile, based on publicly available information

Sean McGinty

Division of Biomedical Engineering, University of Glasgow, Glasgow, UK

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 April 2019 in Advanced Science
Verified
Journal Article
Open access
PDF file
YWYi Wang
Yi Wang
KZKang Zhang
Kang Zhang
XQXian Qin
Xian Qin
TLTianhan Li
Tianhan Li
JQJuhui Qiu
Juhui Qiu
GWGuixue Wang
Guixue Wang
Cardiovascular disease is the leading cause of mortality worldwide. Atherosclerosis, one of the most common forms of the disease, is characterized by a gradual formation of atherosclerotic plaque, hardening, and narrowing of the arteries. Nanomaterials can serve as powerful delivery platforms for atherosclerosis treatment. However, their therapeutic efficacy is substantially limited in vivo due to nonspecific clearance by the mononuclear phagocytic system. In order to address this limitation, rapamycin (RAP)‐loaded poly(lactic‐co‐glycolic acid) (PLGA) nanoparticles are cloaked with the cell membrane of red blood cells (RBCs), creating superior nanocomplexes with a highly complex functionalized bio‐interface. The resulting biomimetic nanocomplexes exhibit a well‐defined “core–shell” structure with favorable hydrodynamic size and negative surface charge. More importantly, the biomimetic nature of the RBC interface results in less macrophage‐mediated phagocytosis in the blood and enhanced accumulation of nanoparticles in the established atherosclerotic plaques, thereby achieving targeted drug release. The biomimetic nanocomplexes significantly attenuate the progression of atherosclerosis. Additionally, the biomimetic nanotherapy approach also displays favorable safety properties. Overall, this study demonstrates the therapeutic advantages of biomimetic nanotherapy for atherosclerosis treatment, which holds considerable promise as a new generation of drug delivery system for safe and efficient management of atherosclerosis.

1 November 2015 in Journal of Controlled Release
Verified
Journal Article
Open access
SMSean McGinty
Sean McGinty
GPGiuseppe Pontrelli
Giuseppe Pontrelli
In this paper we present a general model of drug release from a drug delivery device and the subsequent transport in biological tissue. The model incorporates drug diffusion, dissolution and solubility in the polymer coating, coupled with diffusion, convection and reaction in the biological tissue. Each layer contains bound and free drug phases so that the resulting model is a coupled two-phase two-layer system of partial differential equations. One of the novelties is the generality of the model in each layer. Within the drug coating, our model includes diffusion as well as three different models of dissolution. We show that the model may also be used in cases where dissolution is rapid or not relevant, and additionally when drug release is not limited by its solubility. Within the biological tissue, the model can account for nonlinear saturable reversible binding, with linear reversible binding and linear irreversible binding being recovered as special cases. The generality of our model will allow the simulation of the release from a wide range of drug delivery devices encompassing many different applications. To demonstrate the efficacy of our model we simulate results for the particular application of drug release from arterial stents.

1 November 2014 in Mathematical Biosciences
Verified
Journal Article
Open access
SMSean McGinty
Sean McGinty
Drug-eluting stents have revolutionised the treatment of coronary artery disease. These small medical devices have attracted much interest over the past decade from biologists, clinicians, engineers and mathematicians alike. This article provides a comprehensive review of the modelling of drug release from arterial stents and the subsequent drug transport through arterial tissue, and acts as a useful reference equally for those who are already involved in drug-eluting stents research and for those who are starting out in the field. Assembled in this review are the main models of drug release and arterial drug transport that have been published in the literature to date. Many of the models presented in this paper have evolved from drug transport models in other applications. Furthermore, the ideas presented in this review may also be extended to other drug-delivery applications, such as drug coated balloons, transdermal patches and therapeutic contact lenses.

22 April 2010 in Mathematical Medicine and Biology: A Journal of the IMA
Verified
Journal Article
Closed access
PDF file
SMSean McGinty
Sean McGinty
SMSean McKee
Sean McKee
RWRoger M. Wadsworth
Roger M. Wadsworth
CMChristopher McCormick
Christopher McCormick
In this study, we consider a family of mathematical models to describe the elution of drug from polymer-coated stents into the arterial wall. Our models include the polymer layer, the media, the adventitia, a possible topcoat polymer layer and atherosclerotic plaque. We investigate the relative importance of transmural convection, diffusion and drug-dependent parameters in drug delivery and deposition. Furthermore, we investigate how the release rate from the stent can be altered and examine the resulting effect on cellular drug concentrations.

8 March 2016 in Journal of Mathematical Chemistry
Verified
Journal Article
Open access
PDF file
SMSean McGinty
Sean McGinty
GPGiuseppe Pontrelli
Giuseppe Pontrelli
In this paper we consider drug binding in the arterial wall following delivery by a drug-eluting stent. Whilst it is now generally accepted that a non-linear saturable reversible binding model is required to properly describe the binding process, the precise form of the binding model varies between authors. Our particular interest in this manuscript is in assessing to what extent modelling specific and non-specific binding in the arterial wall as separate phases is important. We study this issue by extending a recently developed coupled model of drug release and arterial tissue distribution, and comparing simulated profiles of drug concentration and drug mass in each phase within the arterial tissue.

19 July 2018 in NPG Asia Materials
Verified
Journal Article
Open access
PDF file
RDRuolin Du
Ruolin Du
YWYazhou Wang
Yazhou Wang
YHYuhua Huang
Yuhua Huang
YZYinping Zhao
Yinping Zhao
DZDechuan Zhang
Dechuan Zhang
GWGuixue Wang
Guixue Wang
In this study, we designed a novel drug-eluting coating for vascular implants consisting of a core coating of the anti-proliferative drug docetaxel (DTX) and a shell coating of the platelet glycoprotein IIb/IIIa receptor monoclonal antibody SZ-21. The core/shell structure was sprayed onto the surface of 316L stainless steel stents using a coaxial electrospray process with the aim of creating a coating that exhibited a differential release of the two drugs. The prepared stents displayed a uniform coating consisting of nano/micro particles. In vitro drug release experiments were performed, and we demonstrated that a biphasic mathematical model was capable of capturing the data, indicating that the release of the two drugs conformed to a diffusion-controlled release system. We demonstrated that our coating was capable of inhibiting the adhesion and activation of platelets, as well as the proliferation and migration of smooth muscle cells (SMCs), indicating its good biocompatibility and anti-proliferation qualities. In an in vivo porcine coronary artery model, the SZ-21/DTX drug-loaded hydrophobic core/hydrophilic shell particle coating stents were observed to promote re-endothelialization and inhibit neointimal hyperplasia. This core/shell particle-coated stent may serve as part of a new strategy for the differential release of different functional drugs to sequentially target thrombosis and in-stent restenosis during the vascular repair process and ensure rapid re-endothelialization in the field of cardiovascular disease.